Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily make copies of Novo Nordisk’s semaglutide. The gambit boosted the telehealth firm’s stock price,

Shares in Hims & Hers Health soared in early-morning trading after it announced a partnership with Wegovy maker Novo Nordisk.

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth platforms. The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own obesity medication,